Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO 140 monotherapy extension in HIV-1 infection
NCT02355184Phase 2Terminated
- Sponsor
- CytoDyn Inc.
- Start
- Nov 2014
- Primary completion
- Jun 2022
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of leronlimab in human immunodeficiency virus type 1 infection (HIV-1), sponsored by CytoDyn Inc. Primary endpoint: Time to Virologic Failure After Initiating PRO 140 Monotherapy up to 125 weeks. Started Nov 2014; status: terminated.
02
Drugs
leronlimab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT02355184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02355184.